Asthma, an allergic disease of the airways, is a risk factor for severity of common respiratory viral infections; however, the relationship between asthma and severity in COVID-19 remains unclear. Here, we examined the effects of SARS-CoV-2 (Omicron BA.5 strain) infection in a mouse model of airway allergy. First, stimulation of allergic mice with OVA resulted in the appearance of ACE2-negative mucus-secreting goblet cells in the bronchiolar region, and an increase in the number of ACE2-expressing cells in the alveoli. As a result, ACE2-expressing cells, which are susceptible to SARS-CoV-2, were limited to the distal portion of the bronchioles while they increased in the alveolar area. After viral infection, the peak infectious viral load in the OVA group was 100-fold lower than that in the phosphate buffered saline (PBS) group; however, clearance of viral RNA from the upper/lower airways was delayed. There were notable differences in acquisition of nsp5 and nsp6 mutations by the Omicron BA.5 strain recovered from BALF samples obtained from the OVA and PBS groups. Immune responses associated with viral clearance were essentially the same, but expression of granulocyte-associated chemokines was higher, M2 macrophage responses were predominant, and the higher spike-specific IgG1/IgG2a ratio in the OVA group post-infection. Infection localized in the alveolar region earlier in the OVA group, resulting in more severe alveolar damage than in the PBS group. These data suggest a Th2-shifted immune background and altered localization of SARS-CoV-2 susceptible cells in mice with OVA-induced airway allergy, which reflect Omicron BA.5 infection dynamics, viral mutations, and immunopathology.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11701410PMC
http://dx.doi.org/10.1111/1348-0421.13184DOI Listing

Publication Analysis

Top Keywords

omicron ba5
16
airway allergy
12
ova group
12
mouse model
8
altered localization
8
ba5 infection
8
infection dynamics
8
dynamics viral
8
viral mutations
8
mutations immunopathology
8

Similar Publications

Article Synopsis
  • - SARS-CoV-2 is still a major cause of death in North America, and this study examines how methotrexate and tumor necrosis factor inhibitors (TNFi) affect vaccine responses in patients with immune-mediated inflammatory diseases (IMID).
  • - Researchers collected and analyzed serum samples from 479 adults with conditions like inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) across Canada to evaluate neutralization responses to COVID-19 vaccination.
  • - The results indicated that both methotrexate and TNFi independently reduced the ability to neutralize the virus, underscoring the need for careful vaccination strategies as COVID-19 remains widespread.
View Article and Find Full Text PDF

Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia.

BMC Infect Dis

August 2024

Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, No.1 Jalan Setia Murni U13/52, Seksyen U13, Shah Alam, Selangor, 40170, Malaysia.

Background: The effect of nirmatrelvir/ritonavir on preventing post-COVID condition (PCC) in the BA4, BA5, and XBB Omicron predominant periods is not well understood. The purpose of this study was to assess how nirmatrelvir/ritonavir treatment affected both PCC and health-related quality of life.

Methods: This retrospective cohort study enrolled 2,524 adults aged 18 years and older who were eligible for nirmatrelvir/ritonavir between July 14 to November 14, 2022.

View Article and Find Full Text PDF
Article Synopsis
  • Although the Omicron variant of SARS-CoV-2 has many mutations, the backbone of its spike protein remains largely the same, providing a stable target for vaccine design.
  • Researchers created several subunit vaccines using this stable backbone along with various receptor-binding domains from different SARS-CoV-2 variants to test their immune response capabilities.
  • The S-6P-Delta-RBD vaccine showed strong effectiveness, generating broad neutralizing antibodies and offering complete protection against severe outcomes from Delta and Omicron infections in mice, indicating its potential as a universal COVID-19 vaccine.
View Article and Find Full Text PDF

Background: Information on Paxlovid™ effectiveness must be monitored and updated in real world scenarios. Our research question was what is the effectiveness of Paxlovid™ in adult patients with COVID-19? Therefore, we investigated the effectiveness of Paxlovid™ on reducing the incidence of pneumonia, hospitalization, and mortality in a cohort of COVID-19 positive adult patients from northeast Mexico.

Methods: A retrospective cohort study of COVID-19 positive adult patients from Nuevo Leon, Mexico from December 2020 to May 2023 (after Omicron BA-5 circulation) was performed.

View Article and Find Full Text PDF

The emergence of the variant of concern Omicron (B.1.1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!